Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson
Dow
Merck
Mallinckrodt

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR CYCLOSERINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cycloserine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000194 ↗ Neurobiology of Opioid Dependence: 3 - 3 Withdrawn National Institute on Drug Abuse (NIDA) Phase 2 1993-01-01 The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
NCT00000194 ↗ Neurobiology of Opioid Dependence: 3 - 3 Withdrawn Yale University Phase 2 1993-01-01 The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
NCT00000371 ↗ Trial of D-Cycloserine in Schizophrenia Completed Massachusetts General Hospital Phase 3 1996-08-01 To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response. Dysfunction of glutamatergic neuronal systems has recently been implicated in the pathophysiology of schizophrenia based on the finding that non-competitive inhibitors of the NMDA receptor can reproduce in normals the positive symptoms, negative symptoms, and cognitive deficits of schizophrenia. Furthermore, glutamatergic dysfunction may alter forebrain dopaminergic neuronal activity, a system central to the antipsychotic action of typical neuroleptics. It is believed that enhancing NMDA receptor function by systemic treatment with D-cycloserine, a partial agonist at the glycine modulatory site of the NMDA receptor, will reduce symptoms in schizophrenia. Sixty schizophrenic outpatients with prominent, primary negative symptoms are treated with antipsychotic medication and are randomly assigned to D-cycloserine or placebo for a 6-month, fixed-dose trial. The primary outcome measure is the total score on the Scale for Assessment of Negative Symptoms (SANS). A neuropsychological battery, which emphasizes tests sensitive to prefrontal cortical function, is administered. Blood is obtained at several time points and CSF is obtained at Week 8 for assay of concentrations of D-cycloserine, glutamate, HVA, and 5HIAA.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cycloserine

Condition Name

Condition Name for Cycloserine
Intervention Trials
Schizophrenia 12
Obsessive-Compulsive Disorder 9
Major Depressive Disorder 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cycloserine
Intervention Trials
Disease 19
Depression 15
Depressive Disorder 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cycloserine

Trials by Country

Trials by Country for Cycloserine
Location Trials
United States 113
China 37
Canada 9
Germany 5
Israel 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cycloserine
Location Trials
Massachusetts 23
New York 15
Texas 9
Illinois 9
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cycloserine

Clinical Trial Phase

Clinical Trial Phase for Cycloserine
Clinical Trial Phase Trials
Phase 4 16
Phase 3 15
Phase 2/Phase 3 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cycloserine
Clinical Trial Phase Trials
Completed 73
Recruiting 12
Unknown status 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cycloserine

Sponsor Name

Sponsor Name for Cycloserine
Sponsor Trials
National Institute of Mental Health (NIMH) 15
Massachusetts General Hospital 15
National Institute on Drug Abuse (NIDA) 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cycloserine
Sponsor Trials
Other 192
NIH 29
Industry 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
Colorcon
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.